logo
Healthcare, retirement and leave benefits top employer priorities for 2025, SHRM says

Healthcare, retirement and leave benefits top employer priorities for 2025, SHRM says

Yahoo3 days ago
This story was originally published on HR Dive. To receive daily news and insights, subscribe to our free daily HR Dive newsletter.
Employee health coverage remains a top priority for employers this year, with 88% of the nearly 4,000 HR professionals who responded to SHRM's benefits survey rating health benefits extremely or very important to their organization.
The survey, released June 30, captured responses from U.S.-based SHRM members representing organizations with two to more than 50,000 employees in a wide variety of industries and sectors across the U.S., SHRM said. Almost all reported that their organization provides general health plan coverage (97%), dental insurance (99%) and vision insurance (96%).
Retirement savings and planning benefits (81%) tied with leave benefits (81%) for the fourth consecutive year as the second most important benefits priority for employers, the survey found.
In 2025, HR professionals find themselves dealing with complex, contradictory challenges, and this is no less so when it comes to prioritizing employee benefits, which must both attract and retain talent and keep costs in check, recent studies show.
One notable example is the emergence of GLP-1 drug coverage for type 2 diabetes and weight management. SHRM asked about it for the first time this year.
The drug is popular with employees, and 23% of organizations provide coverage for it, the SHRM survey found.
But it's expensive — about $700 to $800 per month — and a major contributor to pharmacy costs, the primary reason healthcare expenses are rising, according to a 2024 report by the Business Group on Health.
Rising healthcare costs are the top issue influencing benefit strategies, 90% of almost 700 U.S. employers told WTW in a recent survey.
Almost three-quarters (73%) of employers plan to address high costs by enhancing value or switching to better-value vendors for health, retirement and risk benefits, the survey results, released in June, showed. More than 4 in 10 (44%) employers plan to tackle high-cost medical conditions, and 37% said they plan to adopt a network of preferred medical providers.
As for retirement savings and planning benefits, 93% of the HR professionals who responded to the SHRM survey said their organization offers a traditional 401(k) or similar defined contribution plan. Of those, 85% offer a 401(k) employer match, with an average match of 6.3%, the survey found.
Retirement benefits are critical to a majority of workers across generations, who believe they could work until retirement and still not have enough money saved to meet their needs, according to a June report from the Transamerica Center for Retirement Studies and Transamerica Institute.
Access to meaningful employment with retirement benefits throughout their working years is the single most important ingredient for workers to achieve a financially secure retirement, the CEO of Transamerica Institute stated.
Discouragingly for employees with student loan debt, only 4% of SHRM survey respondents said their employer matches 401(k) or 403(b) contributions based on an employee's student loan repayment, a benefit made possible by the SECURE Act 2.0, SHRM found.
Also, despite the risk of losing talent without paid caregiver leave, especially for employees in the 'sandwich generation,' according to a June report from Prudential, paid leave for care for immediate family members and extended families took a step back in 2025, dropping to 31% and 17% respectively, the SHRM survey showed.
Recommended Reading
7 stories on the importance of vacation
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Eli Lilly and Company (LLY): I Would 'Love' If Trump Praised The Company, Says Jim Cramer
Eli Lilly and Company (LLY): I Would 'Love' If Trump Praised The Company, Says Jim Cramer

Yahoo

time4 hours ago

  • Yahoo

Eli Lilly and Company (LLY): I Would 'Love' If Trump Praised The Company, Says Jim Cramer

We recently published . Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. Eli Lilly and Company (NYSE:LLY) is one of the most frequently discussed pharmaceutical stocks on Cramer's morning show. Over the course of this year, the CNBC TV host has maintained that the firm enjoys a lead in the weight loss drug market and aims to further expand its dominance by developing a robust manufacturing base. Cramer also believes that Eli Lilly and Company (NYSE:LLY) will benefit from introducing a weight loss pill along with a strong pipeline of drugs that targets diseases such as hypertension. His recent comments focused on an analyst note: '[On a Mizuho note saying POTUS would praise LLY and JNJ] I would love that, that won't happen. You know why it won't happen? See there's someone in the health and human services department that's not crazy about, about big pharma and the way we think about it. So there's not going to be a party thrown for you at Lilly. You know that GLP-1 is not a favorite of RFK Jr. Not a favorite. So no, no party for them.' Earlier, Cramer discussed Eli Lilly and Company (NYSE:LLY)'s CEO and investor expectations: 'David Ricks, if you spend time with him, has a view, of what should be done, that ends with the pill that you take every day, no shot . . but everyone's thinking that he doesn't have anything in the hopper. He's got heart coming up, he's going to have Alzheimer's coming up, oh buy. An array of pharmaceutical pills with the company's logo on the bottle. 'It's going be a trillion-dollar market cap, Ken Langone told me that. He's one of the largest investors in Lilly. He knows. While we acknowledge the potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.

Tandem Diabetes, Solventum, LeMaitre, UFP Technologies, and Artivion Stocks Trade Down, What You Need To Know
Tandem Diabetes, Solventum, LeMaitre, UFP Technologies, and Artivion Stocks Trade Down, What You Need To Know

Yahoo

time19 hours ago

  • Yahoo

Tandem Diabetes, Solventum, LeMaitre, UFP Technologies, and Artivion Stocks Trade Down, What You Need To Know

A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. The wider market sentiment turned negative after the White House announced plans to impose a 35% tariff on Canadian imports, sparking renewed fears of a trade war. This news prompted a sell-off across major U.S. indexes, including the S&P 500 and the Dow Jones Industrial Average, as investors grew concerned about the potential economic impact of escalating protectionist policies. The healthcare sector is especially vulnerable to such tensions due to its deeply integrated supply chains with Canada for pharmaceuticals and medical devices, meaning increased costs and potential disruptions. Additionally, ongoing U.S. policy headwinds aimed at lowering drug prices and specific corporate challenges, like those faced by UnitedHealth Group, further compounded the sector's decline. As a result, the Health Care SPDR ETF (XLV) fell 1.0%, underperforming even as major indices pared some losses. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Healthcare Technology for Patients company Tandem Diabetes (NASDAQ:TNDM) fell 3.3%. Is now the time to buy Tandem Diabetes? Access our full analysis report here, it's free. Surgical Equipment & Consumables - Diversified company Solventum (NYSE:SOLV) fell 3.1%. Is now the time to buy Solventum? Access our full analysis report here, it's free. Surgical Equipment & Consumables - Specialty company LeMaitre (NASDAQ:LMAT) fell 3%. Is now the time to buy LeMaitre? Access our full analysis report here, it's free. Drug Development Inputs & Services company UFP Technologies (NASDAQ:UFPT) fell 3.4%. Is now the time to buy UFP Technologies? Access our full analysis report here, it's free. Medical Devices & Supplies - Cardiology, Neurology, Vascular company Artivion (NYSE:AORT) fell 3%. Is now the time to buy Artivion? Access our full analysis report here, it's free. UFP Technologies's shares are very volatile and have had 22 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. UFP Technologies is down 1% since the beginning of the year, and at $243.73 per share, it is trading 32% below its 52-week high of $358.42 from September 2024. Investors who bought $1,000 worth of UFP Technologies's shares 5 years ago would now be looking at an investment worth $5,398. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition
MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition

USA Today

timea day ago

  • USA Today

MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition

SKNY-1 was previously shown to achieve up to 30% weight loss, reverse nicotine craving, and preserve muscle mass in an animal model-and is designed to avoid the CNS side effects that halted earlier CB1-targeting drugs MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) today announced new preclinical results from SKNY-1, an oral drug candidate for obesity and nicotine addiction currently under definitive agreement for acquisition. In a validated behavioral model used to measure Cannabinoid 1 receptor (CB1) related anxiety-like effects, SKNY-1 demonstrated clear reversal of anxiety-related behavior induced by a CB1 activator, setting it apart from earlier CB1-targeting drugs that were discontinued due to serious central nervous system (CNS) effects. SKNY-1 is being developed as a potential oral treatment for obesity and addiction. It has previously been shown to achieve up to 30% weight loss, reverse high-calorie food and nicotine cravings, and preserve muscle mass in preclinical models. These new findings suggest that SKNY-1 may deliver these therapeutic effects without emotional or behavioral disruption, an important factor in long-term treatment adherence. 'These findings are a significant step forward,' said Erez Aminov, Chief Executive Officer of MIRA. 'The ability to suppress appetite and cravings while reversing anxiety-like effects is critical. These results reinforce the differentiated approach behind SKNY-1 and its potential role as a novel oral treatment in large, underserved markets.' About the Study The study used the light-dark preference test in zebrafish-a validated behavioral model to assess anxiety-related responses. Zebrafish naturally prefer darker environments due to an innate fear of predators. However, when anxiety levels are elevated, they avoid the light even more strongly spending more time in the dark. Reduced dark preference (i.e., more time in the light) is interpreted as a calming effect. Four groups were evaluated: Control Group (No Drug): Fish showed balanced behavior between light and dark environments. CP55,940 Group (CB1 Agonist): These animals spent significantly more time in the dark, confirming that CB1 activation increases anxiety at higher doses. Interestingly, at lower doses, CP55,940 produced a calming effect-reducing dark preference and encouraging exploration of the light area. Rimonabant Group (CB1 Inverse Agonist): Fish treated with Rimonabant also showed increased dark-zone time and exhibited a greater increase in anxiety-like behavior than the CB1 agonist group, under both high and low doses of agonist-consistent with the known psychiatric effects that led to Rimonabant's market withdrawal. SKNY-1 Groups: In animals co-treated with CP55,940, SKNY-1 significantly reversed the anxiety-inducing effects of high-dose CP55,940 and enhanced the calming effects at low doses. In all conditions, SKNY-1 brought anxiety-like behavior back to control or better-than-control levels. These results suggest SKNY-1 may help stabilize mood and stress-related behavior-a potential advantage in treating both metabolic and addictive disorders. A New Approach to Endocannabinoid Modulation SKNY-1 targets the endocannabinoid system (ECS)-a key regulator of hunger, emotion, reward, and addictive behavior-through a multi-pathway approach: Biased CB1 antagonism blocks β-arrestin signaling (linked to cravings and compulsive behavior) while preserving G-protein signaling (important for emotional regulation). CB2 partial agonism may reduce inflammation in the brain, which is increasingly recognized as a driver of anxiety, depression, and cognitive decline. By lowering neuroinflammation, SKNY-1 may help preserve emotional balance and support cognitive resilience. Mild inhibition of MAO-B regulates dopamine, which plays a role in motivation and behavioral control. No inhibition of MAO-A confirmed through in vitro screening-important because MAO-A inhibitors are associated with mood instability, drug interactions, and safety concerns. This multi-target profile gives SKNY-1 a differentiated mechanism that may allow it to reduce cravings and weight while supporting emotional health-without the psychiatric side effects that limited earlier CB1 or MAO-based drugs. 'The ability to block cravings while preserving emotional balance is a key challenge in this field,' said Dr. Itzchak Angel, MIRA's Chief Scientific Advisor. 'SKNY-1 appears to meet that challenge head-on. The demonstration that its profile is significantly different than rimonabant in its interaction with CB1 agonists, reinforces the unique pharmacological profile of the drug.' Market Opportunity Obesity and addiction are among the most urgent and expensive public health challenges globally. In the U.S. alone, the economic burden of obesity and related chronic diseases is estimated at $1.7 trillion annually, equivalent to over 9% of the nation's GDP (Milken Institute, 2023). Yet despite significant commercial investment, current therapies remain limited by efficacy gaps and tolerability challenges. Current GLP‑1 therapies like semaglutide deliver weight loss but are injectables, often cause gastrointestinal side effects, and can result in loss of lean muscle mass. Smoking cessation therapies such as varenicline or bupropion offer modest long-term success and may carry psychiatric warnings that restrict their use in sensitive patient populations. Earlier CB1-targeting drugs, including rimonabant, were withdrawn due to severe mood disorders. Furthermore, broad MAO inhibition-especially MAO‑A-has long been associated with mood instability and dangerous food-drug interactions. SKNY‑1 was developed to address those limitations directly. With oral administration, differentiated pharmacology, and potential dual efficacy in obesity and nicotine addiction, SKNY‑1 may offer a best-in-class profile. Its lack of MAO‑A inhibition, confirmed in vitro, further enhances its therapeutic promise. Next Steps MIRA is currently preparing for shareholder approval related to the proposed acquisition of SKNY Pharmaceuticals, Inc. Pending approval, the Company expects to initiate Investigational New Drug (IND)-enabling studies for SKNY-1 as a next step toward human clinical trials. About MIRA Pharmaceuticals, Inc. MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in areas such as neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. Cautionary Note Regarding Forward-Looking Statements This press release and the statements of MIRA's management related thereto contain 'forward-looking statements,' which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will,' and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA's potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at and on MIRA's website at MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact: Helga Moya info@ (786) 432-9792 SOURCE: MIRA Pharmaceuticals View the original press release on ACCESS Newswire

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store